In data evaluated from clinical studies to date, ivospemin has not shown exacerbation of bone marrow suppression and peripheral neuropathy, which can be chemotherapy-related adverse events.

Carta Healthcare, a leading provider of AI-powered clinical data abstraction, today announced it has secured $18.25 million in Series B1 financing. This investment will accelerate the company's ...